Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial

OBJECTIVES: This randomised, double-blind, placebo-controlled phase IIIb study evaluated the impact of abatacept on MRI pathology as a primary outcome in methotrexate (MTX)-refractory patients with rheumatoid arthritis. METHODS: Patients received intravenous abatacept (∼10 mg/kg) or placebo, on back...

Descripción completa

Detalles Bibliográficos
Autores principales: Conaghan, Philip G, Durez, Patrick, Alten, Rieke E, Burmester, Gerd-Rüdiger, Tak, Paul P, Klareskog, Lars, Catrina, Anca Irinel, DiCarlo, Julie, Gaillez, Corine, Le Bars, Manuela, Zhou, Xianhuang, Peterfy, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711370/
https://www.ncbi.nlm.nih.gov/pubmed/22915624
http://dx.doi.org/10.1136/annrheumdis-2012-201611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711370/
https://www.ncbi.nlm.nih.gov/pubmed/22915624
http://dx.doi.org/10.1136/annrheumdis-2012-201611

Ejemplares similares